Parsabiv Approval History
- FDA approved: Yes (First approved February 7, 2017)
- Brand name: Parsabiv
- Generic name: etelcalcetide
- Dosage form: Injection
- Company: Amgen Inc.
- Treatment for: Secondary Hyperparathyroidism
Parsabiv (etelcalcetide) is a calcium-sensing receptor agonist indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Development History and FDA Approval Process for Parsabiv
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.